Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Then, if you read the highlighted portion of the post by aries 4747, you will see the IV-Cell product is replacing an inferior product sold by Thermo Fisher. Wonder if they will be interested in buying or licensing IV-Cell, or just buying Precipio.... Either way the rocket is ignited!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136899073
aries4747
Thursday, 12/14/17 01:56:32 PM
Re: None
Post # of 1654
PRPO:Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media
Commercialization plans include third-party validation of the media, alongside discussions with potential industry players to acquire product rights and associated IP
December 14, 2017 08:00 ET | Source: Precipio, Inc.
NEW HAVEN, Conn., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ:PRPO), today announced the recent filing of a patent application for IV-Cell, a novel media (reagent) developed by Precipio and validated in collaboration with Yale University faculty. The media has been developed, validated, and used in over 100 clinical cases in Precipio’s CLIA laboratory. The Company’s strategy is to bring this product to a commercialization-ready state, and then license or sell the product and associated IP to one of the major industry players who have manufacturing and distribution capabilities for this market.
The media was developed by Ayman Mohamed, Precipio’s VP of R&D, as a solution to an industry-wide problem. When a clinical laboratory receives a patient specimen for diagnosis, it selects various tests in order to arrive at a diagnosis to confirm or rule out the physician’s clinical question as to the type of cancer the patient may have. As part of the evaluation of blood-related cancers, cytogenetics testing is often critical to answering that question through a process of cell culturing. In that process, the laboratory selects a cell lineage of interest based on the clinical question, and cultures those cells from the patient specimen, in an attempt to mimic the body’s development of such cells. If those cells present an abnormality during the culturing process, that can indicate a certain malignancy. In evaluating blood-related cancers, the laboratory must select one of four possible cell lineages to conduct the cell culturing; once that lineage is selected to be cultured, the laboratory is unable to “change” its selection, or repeat the test on other cell lineages. Therefore, if the incorrect cell lineage is selected, the test is wasted; moreover, the results will not contribute any relevant information to the diagnosis, and this could result in an incomplete and often inaccurate diagnosis returned to the physician.
Precipio’s IV-Cell was designed to enable the laboratory to culture all four cell lineages simultaneously (hence the name IV). Rather than having to select only one of four different media (reagents) in order to conduct selective culturing of a single cell lineage, IV-Cell media enables the simultaneous culturing of all four cell lineages in parallel. This is a dramatic departure from conventional cytogenetics practice which forces the laboratory to select one out of the four cell lineages, enabling any laboratory to broaden its investigation of the correct cell lineage that may present an abnormality during the cell culture, and helping to ensure that the laboratory provides the clinician with a more complete picture of the patient’s situation.
Precipio completed the development of the media in February 2017; in April 2017 it completed a full validation in its CLIA laboratory, and began using it replacing MarrowMax™, a product sold by Thermo Fisher. Since then, Precipio has used IV-Cell in over 100 specimens, which have been reviewed and signed out by Precipio’s medical director as well as other faculty at Yale Department of Pathology. IV-Cell is significantly less expensive, reducing the related costs in the Cytogenetics department by over 50% due to the utilization of a less expensive reagent; as well as the ability to reduce inventory from four different media, to one single item (SKU).
“The benefits of IV-Cell cannot be overstated in the clinical hematology diagnostic market,” said Dr. David Hudnall, Precipio’s Medical Director & Professor of Pathology and Laboratory Medicine at Yale University. “This is a problem laboratories have faced for years, and we have always known it has negatively impacted the level of accuracy of our results. The use of IV-Cell in the laboratory has most certainly provided us, as pathologists, more accurate cytogenetic results,” concluded Dr. Hudnall.
Over the next few months, a third party academic laboratory will be conducting external validation to test the reagent in its clinical setting, and independently demonstrate and verify the clinical value of the media. In parallel, Precipio has entered into discussions with several industry players to explore their interest in the product. Various economic models from licensing to acquisition of this product and associated IP are being considered; Rather than become a reagent manufacturer or distributor, Precipio currently believes this invention will ultimately yield the most value through a partnership with one of the industry leaders.
“This is yet another example of the power of Precipio’s innovative spirit, and a demonstration of the value of collaborations between a commercial entity such as Precipio, and an academic environment provided by a university such as Yale,” said Professor Jeffrey Sklar, Chair of Precipio’s Scientific Advisory Board and Professor of Pathology at Yale. “I am confident this will change the way cytogenetic cell cultures are handled, and impact the accuracy of diagnosis wherever it is used. This is a significant invention, and I am delighted to be associated with the team that created it,” concluded Dr. Sklar.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
The company seems to finally on a good track. This news is very encouraging, and if you read the portion I highlighted, it could very well ignite the rocket....
Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania
NEW HAVEN, Conn., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics firm Precipio, Inc. (NASDAQ:PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of Pennsylvania to conduct an external validation and evaluation of IV-Cell, Precipio’s cytogenetics media.
The market for cytogenetics media is estimated to exceed $100M annually; most of the cytogenetics reagents have seen little development in the past 25 years, presenting an opportunity for a breakthrough media such as IV-Cell.
Validation by an external laboratory represents the first step in bringing this product to market. The completion of this study is expected to provide strong, independent evidence of its performance, and will serve as an important tool during discussions with the leading manufacturers to acquire this technology.
Study Goals
The study will be conducted over a period of approximately six to eight weeks and will include the testing of over 50 clinical specimens. During the study, the Penn team will do a side-by-side comparison between their current culture media, and Precipio’s media.
The study will evaluate two key elements of Precipio’s media. First, its ability to enable laboratory technicians to culture multiple cell lineages simultaneously compared to their existing media that requires the laboratory to select up-front the target cell lineage; once that cell lineage is selected, it cannot be changed. The ability to culture multiple cell lineages using IV-Cell represents a significant advantage that can provide the laboratory with a more complete picture of the patient specimen, and can ultimately lead to a more accurate diagnosis.
The second advantage, is a significantly higher resolution of the chromosomal bands that are created during the process. This increases the cytogeneticists’ ability to correctly identify any abnormalities that may be present, resulting in a more accurate diagnosis.
"If the trial in our laboratory successfully demonstrates that Precipio’s IV-Cell media works, it could be very useful in the field of cytogenetics,” said Jennifer Morrissette, PhD, Associate Professor of Clinical Pathology and Clinical Director of the Center for Personalized Diagnostics in the Perelman School of Medicine at the University of Pennsylvania.
Precipio developed the cytogenetics media earlier in 2017 and has been using it clinically in its laboratory for the past six months. IV-Cell has been successfully applied on more than 100 clinical patient cases. In parallel with this validation study, Precipio continues to dialogue with industry manufacturers to discuss a potential license or acquisition of the IP generated from this invention.
"We are delighted to have partnered with a prominent laboratory such as the one at the University of Pennsylvania to conduct this trial. Their immediate interest in setting up a trial, as well as their enthusiasm in a joint publication and presentation in the upcoming American Cytogenetics Conference, the industry’s leading conference, is a testament to the exciting breakthrough potential of our product,” said Ilan Danieli, President and Chief Executive Officer of Precipio. "We look forward to a close collaboration with Penn, and are eager to see the results of their experience using the media, and its potential impact on clinical care. Ultimately this goes directly to our vision of reducing diagnostic errors and saving lives through multiple avenues, combining academic expertise and innovation to deliver a more accurate diagnosis," Mr. Danieli concluded.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Great Find...Thank you for posting.
And GO BLUE!
Abeta...
Thank you for all your work today.
That statement seems extremely powerful and explosive!
These were LP's words today?
As we reported in ASCO last year, a huge number of patients, way more than expected, were still alive. We have to weigh that... how much of an additional home run would we get if we continue vs. going with what we have now.
I am not referring to AF and his rule.
I am saying they were bought out before being approved.
The thing is Celator, CPXX, was never approved by FDA before being bought out. So, Basin Street Blues is right!
Agreed. Especially when Les tells him he knows nothing about Naked Short Selling.
He has been harping on this for years. Did you all expect him to say that AA is coming in 6 weeks and a buyout in 3 months? No, at this point you get nothing, even if all of this is indeed going on. There have been a lot of steps taken in the last couple of months. Read the CPXX board. Price went up and back down. Sounded just like this board. Then.....WHAM!
I understand. Still does not mean it is not in play.
I have a question regarding the share increase.
In a buyout, I am told, the unauthorized shares can just be acquired by the buyer, with no vote necessary. TC, any thoughts, as this should be in your wheelhouse.
If I read the proxy correctly, the vote on executive compensation is basically meaningless...
2. To hold an advisory vote on executive compensation.
So there really is nothing to vote on of any great importance.
A director and an accounting firm. Pretty bland stuff to go to all this trouble and expense of calling shareholders. Unless of course you subscribe to TC's theory of finding out how many naked shorts there really are there. There is also #4.
4. To act upon other matters as may properly come before the meeting or any adjournment thereof.
Celator Pharma...CPXX
Stock was stuck between $1 and $2 dollars.
They announced top line positive results, stock shot up to $10 plus.
Thirty days later bought out for $30.
Had only one drug and no approval.
Celgene to buy Juno....
https://www.bloomberg.com/news/articles/2018-01-16/juno-therapeutics-shares-surge-on-report-of-celgene-deal-talks
NWBO next?
Both CYRX clients.
https://twitter.com/KrstevskiBranko
Branko Krstevski?
@KrstevskiBranko
Follow
Follow @KrstevskiBranko
More
Replying to @akikadog1
Hi Akika!
I remain bullish about $NWBO.
I have invested in their current private placement.
Am looking forward to Phase3 results.
Happy New Year & GL!
I agree wholeheartedly. I have warrants from that raise, and didn't blink an eye from the offer.
This seems like pretty good news....What do you think?
NEWS...
https://finance.yahoo.com/news/precipio-launches-second-ice-cold-130000219.html
Precipio Launches Its Second New ICE-COLD PCR™ Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies On Sanger Sequencing Platforms
GlobeNewswire•December 20, 2017
Comment
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Precipio, Inc. (PRPO), announced today the launch of the second new version of its ICE-COLD PCR™ (ICP) enrichment kit, used to identify resistance mutations in non-small cell lung cancer (NSCLC) using liquid biopsies. As part of the transformation of ICP to be platform-agnostic, this kit has been adapted to be used on Sanger Sequencing platforms, a widely used DNA sequencing method in molecular diagnostics. Precipio's newly designed multiplexed kit enables laboratories using Sanger Sequencing platforms to now adopt the ultra-sensitive, low cost solution that ICP offers.
"Sanger Sequencing is one of the most prevalent and commonly used platforms for molecular diagnostics. In use for 40 years, it is reliable, easy to use, and very economical to run,” said Jeffrey Sklar, MD, PhD, Chairman of Precipio's Scientific Advisory Board. “This kit expands the reach of ICP to laboratories using Sanger Sequencing, giving physicians access to important testing capabilities for ongoing diagnoses and continued monitoring of their patients," Dr. Sklar added.
Precipio's multiplexed ICP kit offers major improvements to current sequencing technologies and platforms, primarily the ability to detect genetic mutations in liquid biopsies such as blood samples. ICP delivers a 100 – 500-fold increase in mutation detection sensitivity (depending on the platform used) compared to current methodologies. Precipio's new kit, offered at a fraction of the cost of competing assays, provides the only economically-viable product on the market enabling laboratories to conduct repeat testing to consistently monitor patients. Hospitals that already conduct such genetic testing on solid tumor biopsies can implement ICP in several days and substantially expand the test menu they offer, alongside increasing their revenue and profitability.
"As promised, our R&D team continues to execute on our plan and deliver our growing product pipeline, on schedule. The launch of our second ICP kit for Sanger, follows the release of our first kit for qPCR platforms, and demonstrates the continued work to create a robust, platform-agnostic offering," said Ilan Danieli, President and Chief Executive Officer of Precipio. "The product we launched today again fulfils our promise to bring to market a comprehensive new line of products that provide solutions to a diverse set of customers, including hospitals, reference laboratories, CROs and others, delivering the promise of liquid biopsy to benefit as many patients as possible," Mr. Danieli continued.
This new product continues the expansion of the market potential for ICP by providing additional revenue-generating products for hospitals. When a cancer patient undergoes treatment at a hospital, testing is required for either initial diagnosis, or continued monitoring of disease progression and the patient’s ongoing response to treatments. Currently, there are limited testing options for hospitals to monitor their patients, which typically involve outsourcing testing to a specialty diagnostic laboratory. Sending these tests to outside laboratories means losing control of the samples; no access to data being generated from these tests; and loss of revenue. ICP gives hospitals the ability to conduct these tests in-house, without having to rely on outside specialty labs. For a hospital laboratory with the existing ability to perform Sanger Sequencing, this represents high-margin, add-on revenue with very little cost, since the hospital already has the equipment and the personnel required to perform these tests.
All ICP kits are designed to target actionable genes and mutations only with associated billable codes, therefore hospitals performing these tests, can, in fact, bill and generate revenue rather than incurring the cost of sending it to an outside laboratory.
The new kit using ICE-COLD PCR™ averages a cost per test of approximately $150; hospital revenue per test is approximately $600, creating a profitable service model for hospital laboratories with generous profit margins. As an example, a 500-bed hospital that would care for an estimated 200 lung cancer patients annually, who can be monitored every 3-6 months, would run an estimated 400-800 tests per year, generating revenues of $250,000-$500,000 per year from this one test kit.
As Precipio continues to develop and release new kits for different cancer types (colon, breast, melanoma, etc.), hospitals that are already set up with ICP technology can easily onboard additional kits for other types of cancer. This enables the hospital to generate revenues exceeding $1M across various types of cancer, while maintaining full control over the specimen, service and the data being generated. By the end of 2018, Precipio plans to have a total of 5-7 cancer-specific kits available for hospitals to use, resulting in a hospital account generating annual revenue to Precipio of approximately $200,000-500,000. With approximately 6,500 hospitals in the US market, this represents a significant market opportunity for Precipio.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Thanks.
I wasn't saying the news was irrelevant. I thought at the time it was good news. When reposted, I was looking for another additional client with revenue, and could not locate a news release that day. Apologies to all.
Todays news was welcome also. Be glad to get tax loss selling over with.
So, this is old news?
Is this new news, and if so, do you have a link?
TIA
Les is a Democrat, but he does have connections to Trump and his purchase of his winery in Charlottesville, Virginia. I hear the wine is pretty good.....
I bought a preferred offering once, with common and warrants.
Both were locked up for at least 6 months, and then they had to be converted to shares. I did receive interest, which was also converted to common. The shares are unavailable until released by the wording in the offering and are not registered until released. Then conversion takes a couple of weeks. Hope this helps.
Ice, I am with you. No one has what we have. The market will realize it when the money starts to flow in, or when Jerry feels comfortable enough to give some guidance. Loads of pokers in the fire.
There really is not enough liquidity for the institutions to get any size w/o moving the price substantially. Maybe a forward split around 15 or 20.......
Not Northwest Bio.
They are tight on money but Phase 3 ready to read out in the near term....They are probably one they are counting on in their 2 to four more.
BTW, Hyper, maybe you can get a beach house behind mine...LOL
Nice run going on at NWBO the last few days.
I am wondering about this dilution. How do we know this is dilution, and not some hedge fund doing a capital raise and shorting us down to the price they want to pay. They are probably directing the MM on what price they want. I HOPE I AM WRONG.....
I guess my question would be, why cover the warrant, if it is going to expire worthless in 5 weeks?
I admit, I am a long time shareholder of Northwest. The risk/reward on this stock right now is off the charts. Kite and Novartis will take longer to ramp because they need to build out capacity. Not so with Northwest.
They have to large facilities in Memphis and Sawston, England. We will see revenue rather quickly if approved.
Ceo Linda Powers has loved Cryoport since at least 2014. Hyper, I was debating to write about this. Glad you beat me to it and gave me a nudge.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106116070
BTW, Northwest is not a one drug wonder, but a platform for all solid tumor cancers. If approved, I will have my beach house....LOL
It seems this is your goal....to crush this stock.
I am more in this camp.
Financiers shorting to keep price down, and will replace with shares in placement. Hope I am wrong, and good news is imminent!
I am confused. Why would anyone exercise these warrants?
Just buy the common, or wait for news. Makes no sense to me.
Prove the futility recommendation, or stop spreading FUD.
Precipio's ICE COLD-PCR(TM) Technology Selected by the University of Kentucky for Liquid Biopsy Study
[ACCESSWIRE]
ACCESSWIREOctober 17, 2017
Research Study to Focus on Actionable Mutations in Non-Small Cell Lung Cancer (NSCLC)
NEW HAVEN, CT / ACCESSWIRE / October 17, 2017 / Precipio, Inc. (PRPO), announced today that its ICE COLD-PCR™ technology has been selected for a study to identify clinically actionable mutations in Non-Small Cell Lung Cancer at the University of Kentucky's Markey Cancer Center, a National Cancer Institute (NCI)-designated center.
"The study will focus on actionable mutations for non-small lung cancer in EGFR, KRAS and BRAF," said Dr. Kurt B. Hodges, Director, Molecular Oncology Services, who will lead the study. "Our goal is to use this technology to identify patients with clinically actionable mutations in NSCLC and then monitor these patients for treatment response via resistance mutations to commonly prescribed NSCLC drugs. Our department has considered numerous technologies for this study, and concluded that Precipio's ICE COLD-PCR™ (ICP) was the most suitable because ICP is a non-allele specific technology with a sensitivity that will allow our laboratory to cost-effectively pick up critical clinically actionable mutations at very low levels in plasma and test for these mutations at several time points over the course of therapy."
The study is scheduled to commence during the fourth quarter of 2017 and is expected to enroll 100 patients. This research study investigates the potential for the technology as a cutting-edge, cost-effective solution that enriches mutations to achieve a high level of sensitivity. Given the design of research studies such as this to conduct repeat testing over time to monitor disease progression, there is a substantive need for an inexpensive, cost-effective solution that creates a feasible, economically viable application of the promise of liquid biopsies.
"We are delighted to partner with the University of Kentucky to support this important research study, especially in light of the recent launch of our first re-designed ICE-COLD PCR™ targeted enrichment kit," said Ilan Danieli, President and Chief Executive Officer of Precipio. "While the field of liquid biopsies is undoubtedly going to change the way cancer is treated over the next few years, valuable research like this is still needed to establish clinical validity and applicability of blood-based samples and corresponding technologies. Academic centers play a key role in the forefront of research to establish these standards, and we are honored to be a part of that process. Precipio is committed to playing a key role in working with researchers and academic institutions to help demonstrate the value of ICE COLD-PCR™ as a leading technology within the liquid biopsy field," Mr. Danieli concluded.
ICE COLD-PCR™ delivers up to a 500-fold increase in mutation detection compared to most current methods, with levels of detection down to 0.1%, making it an ideal method for liquid biopsy analyses. As a low-cost product, it provides a game-changing alternative to competing high-priced liquid biopsy platforms as an economically viable technology that enables low-cost repeat testing.
About University of Kentucky's Markey Cancer Center
The UK Markey Cancer Center was founded in 1983 and is a dedicated matrix cancer center established as an integral part of the University of Kentucky and the UK HealthCare enterprise. It has provided state-of-the-art cancer care for more than 20 years. Markey is the only cancer center in Kentucky designated by the National Cancer Institute. In August 2017, Markey was designated as one of the Top 50 Cancer Centers in the nation by U.S. News & World Report. Markey Cancer Center provides access to more than 100 nationally sponsored clinical studies for different types of cancer. It is among the few institutions nationwide providing multidisciplinary care through Clinical Care and Research Teams (CCARTs). Major CCARTs include breast, gynecologic, gastrointestinal, head and neck, lung, brain, hematologic and genitourinary cancers.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
https://finance.yahoo.com/news/precipios-ice-cold-pcr-tm-120000416.html
If you think it is garbage, keep on moving, nothing for you to see here.
Precipio Launches Its First Re-Designed ICE-COLD PCR(TM) Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies
[ACCESSWIRE]
ACCESSWIREOctober 12, 2017
New Ultra-sensitive Kit Can Help Laboratories Generate Results in as Little as 4-6 Hours at a Significantly Reduced Cost
NEW HAVEN, CT / ACCESSWIRE / October 12, 2017 / Precipio, Inc. (PRPO), announced today that it has launched the first commercially available Research Use Only ICE-COLD PCR™ enrichment kit, to identify resistance mutations in non-small cell lung cancer (NSCLC) using liquid biopsies. The kit is designed to enable the detection of critical lung cancer mutations T790M and C797S, using its proprietary ICE-COLD PCR™ (ICP) technology. Precipio's newly redesigned kit represents the first liquid biopsy enrichment kit of its kind to deliver rapid turnaround, and give laboratories the ability to conduct cost-effective research to identify the presence or absence of these critical resistance mutations.
"Precipio's new enrichment kit will enable laboratories to run the most cost-effective resistance mutation panel on the market, tested using liquid biopsy samples rather than tumor tissue. An assay using ICP yields results quickly, and creates exciting opportunities for researchers to obtain a deeper understanding of the biology of a patient's tumor," said Jeffrey Sklar, MD, PhD, and Chairman of Precipio's Scientific Advisory Board "Using Precipio's ICP enabled tyrosine kinase inhibitor (TKI) Resistance kit, any laboratory that has a qPCR platform will be able to run liquid biopsy testing on resistance mutations with no additional capital expenditures."
Precipio's multiplexed ICP kit offers major advantages over current sequencing technologies that don't include its mutation enrichment technology. ICP delivers a 100-500 fold increase in mutation detection sensitivity (depending on the platform used) compared to current methodologies. Furthermore, its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using a blood sample, providing an opportunity to capitalize on the potential of the pioneering field of liquid biopsies. Lastly, at a price point that is a fraction of the cost of competing assays, Precipio's kit offers the only economically-viable product on the market enabling laboratories to conduct repeat testing.
"I'm thrilled to announce the launch of our first redesigned ICP kit, so soon after the completion of the merger. Our R&D team has been working tirelessly to revamp the previous product into our new kit, delivering a robust, easy to use and low-cost product we can get to the market quickly," said Ilan Danieli, President and Chief Executive Officer of Precipio. "Over the past months, our team has conducted a thorough technical investigation, streamlined production and simplified our previously complex pricing structure, to the benefit of the customer. We have reduced our COGS by over 50%, which will enable Precipio to offer attractive pricing to our customers. The product we launch today marks the beginning of a comprehensive new line of products that meet market demand, and begins to unlock the full potential of ICP as a game-changing technology in the liquid biopsy market," Mr. Danieli continued.
Precipio will be launching additional research use only kits in the coming quarters for other forms of cancer, with various genes and exons that utilize the multiplexed ICP technology. "Our goal is to continue to expand our menu of multiplexed ICP products that include clinically actionable mutations that laboratories around the world can use in a practical, efficient, and economically viable manner," Mr. Danieli concluded.
https://finance.yahoo.com/news/precipio-launches-first-designed-ice-120000575.html
I'll bet if the longs on this board alone counted up all their shares, it would total over 3.6 million. I have 100,000....
Flip,
You are correct.